| Literature DB >> 35310686 |
Yanhui Zhu1,2, Chengwei Zou2, Jun Zhang2, Lei Chen2, Yanting Jia1,2.
Abstract
Purpose: The prognosis of mitral valve replacement is an important clinical issue and may produce unexpected mortality rates if not properly addressed. The postoperative examination results have important prognostic implications. This study was designed to determine the prognostic value of phosphocreatine and inflammatory markers after mitral valve replacement. Method: Comparison and analysis of the data obtained using SPSS software. The computer retrieved PubMed, Science Citation Index (SCI), Embase, VIP, CNKI, CBM, and Wanfang database and manually retrieved randomized controlled trials (RCTs) published at home and abroad on the central muscle protection role of creatine phosphate in heart valve replacement, and the search period was established until February 2018. Two random literature reviewers independently screened the literature and extracted data, using Review Manager (RevMan) (Computer program), version 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, 2014). RevMan software version 5.0 assesses the risk of bias for inclusion in studies. The software performs a meta-analysis of the obtained data.Entities:
Year: 2022 PMID: 35310686 PMCID: PMC8933105 DOI: 10.1155/2022/1132452
Source DB: PubMed Journal: Appl Bionics Biomech ISSN: 1176-2322 Impact factor: 1.781
Basic characteristics of included literature.
| Inflammatory marker | ||
|---|---|---|
| Literature | Document | 15% different from the heart rate |
| Soluble molecules, such as the content and selection of adhesive cells | Changed | The survey is 15% |
| Cytokines | Changed | Less than 100% contaminated and 15% in other conditions |
| HS-CRP | Stable | >15% |
| LVEVDI | Changed | 100% explosives |
| RBC, HBC, and other values | Stir | 18% |
| LVEVDI | Stable | 80% |
| Proenzymes such as CK-MB and proatherogenic enzymes | Stir | 100% |
| C-reactive protein | Changed | 80% |
Statistics.
| Study name | Propensity score matching | No. of participants (repair) | No. of participants (replacement) |
|---|---|---|---|
| DiGregorio (2004) | No | 46 | 13 |
| Ailawadi (2008) | No | 70 | 47 |
| Chikwe (2011) | Yes | 227 | 95 |
| Nloga (2011) | No | 75 | 54 |
| Silaschi (2016) | Yes | 63 | 63 |
| Chivasso (2017) | No | 150 | 97 |
| Farid (2019) | Yes | 78 | 78 |
| Seese (2020) | No | 301 | 171 |
Figure 1ROC curves of RCTs.
Figure 2Comparison of intraoperative cardiac beat rate between the phosphocreatine group.
Figure 3Comparison of CK-MB levels in venous blood 24 h after aorta occlusion between the creatine phosphate group and control group.
Statistical data of prognostic factors.
| Index | No response rate | 95% CL | Sum |
|---|---|---|---|
| Bilirubin (mg/dL) | 1.054 | 1.026 | 0.0001 |
| HGB (g/dL) | 0.694 | 0.600-0.802 | 0.0001 |
| HS-CRP (mg/dL) | 2.654 | 1.546-4.506 | 0.0001 |
| IL10 | 3.506 | 2.571-4.782 | 0.0001 |
| IL6 | 0.403 | 0.260-0.624 | 0.0001 |
| Creatine phosphate | 1.450 |
Figure 4Funnel plot of included studies demonstrating the odds ratios of 30-day mortality in the mitral valve repair group compared to mitral valve replacement group. SE: standard error.